<DOC>
	<DOCNO>NCT00091390</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray source damage tumor cell . Internal radiation therapy use radioactive material place directly near tumor kill tumor cell . Giving radiation therapy different way may kill tumor cell . PURPOSE : This phase II trial study well give internal radiation therapy together external-beam radiation therapy work treat patient stage II stage III prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Stage II Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate late grade 3 great genitourinary gastrointestinal toxicity treatment external beam radiotherapy high-dose rate brachytherapy patient stage II III adenocarcinoma prostate . Secondary - Determine acute grade 3 great genitourinary gastrointestinal toxicity patient treated regimen . - Determine freedom biochemical failure patient treat regimen . - Determine overall survival patient treat regimen . - Determine disease-specific survival patient treat regimen . - Determine clinical relapse ( local and/or distant ) patient treat regimen . - Develop quality assurance process high-dose rate prostate brachytherapy . OUTLINE : This multicenter study . Patients stratify accord prostate-specific antigen ( ≤ 10 ng/mL vs 11-20 ng/mL ) , T stage ( T1c-T2c v T3a-T3b ) , combine Gleason score ( 2-6 v 7 v 8-10 ) , prior hormonal therapy ( vs yes ) , time high-dose rate brachytherapy ( external beam radiotherapy v external beam radiotherapy ) . Patients undergo external beam radiotherapy approximately 15 minute daily 5 day week 5 week . Patients also receive two fraction ( within 24-hour period ) high-dose rate brachytherapy ( deliver implant insert prostate ) approximately 5-30 minute either external beam radiotherapy . Treatment continue absence disease progression unacceptable toxicity . Patients follow 3 , 7 , 9 , 12 month , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 110 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Clinical stage T1cT3b No clinically pathologically involved lymph node ( N0 pelvic CT scan MRI ) No distant metastasis ( M0 negative bone scan ) Meets one follow combination criterion : Clinical stage T1cT2c , Gleason score 26 , prostatespecific antigen ( PSA ) &gt; 10 ≤ 20 ng/mL Clinical stage T3aT3b , Gleason score 26 , PSA ≤ 20 ng/mL Clinical stage T1cT3b , Gleason score 710 , PSA ≤ 20 ng/mL PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Fertile patient must use effective contraception No hip prosthesis No major medical psychiatric illness would preclude study participation No prior invasive malignancy except nonmelanomatous skin cancer ( e.g. , carcinoma situ oral cavity bladder ) malignancy diseasefree status ≥ 3 year PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy prostate cancer Endocrine therapy Prior induction hormonal therapy allow provided therapy initiate within 90 day study enrollment Radiotherapy No prior pelvic prostate radiotherapy No concurrent intensitymodulated radiotherapy Surgery No prior radical surgery prostate cancer No prior transurethral resection prostate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>